- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 87,920 | 30.05.24 11:57:10 | -0,100 | -0,11% | 88,070 | 88,120 | 88,230 | 88,020 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 881,200 | 30.05.24 11:23:31 | -13,800 | -1,54% | 882,800 | 893,000 | 882,200 | 895,000 |
